Ultime notizie per Sunworks (OTC:SUNWQ) Azioni

Sunworks Inc provides photovoltaic (PV) and battery-based power and storage systems for the residential and commercial markets. Commercial projects include commercial, agricultural, industrial, and public works projects. It has three operating segments; Residential Solar offers design, arrangement to finance, integrate, install, and manage systems for residential homeowners, Commercial Solar offers design, arrangement to finance, integration, install, and manage systems ranging in size from 50kW (kilowatt) to multi-MW (megawatt) systems for larger commercial and public works projects, and Corporate segment includes general company oversight and management. The company derives a majority of its revenue from the residential solar segment.

Sunworks Inc

UBS analyst Thomas Wadewitz maintains Old Dominion Freight Line (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ODFL#NASDAQ">ODFL</a>) with a Neutral and lowers the price target from $196 to $158.

News

Price Target

Analyst Ratings

ODFL

UBS Maintains Neutral on Old Dominion Freight Line, Lowers Price Target to $158

UBS analyst Thomas Wadewitz maintains XPO (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPO#NYSE">XPO</a>) with a Buy and lowers the price target from $170 to $108.

UBS Maintains Buy on XPO, Lowers Price Target to $108

UBS analyst Trung Huynh maintains Pfizer (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) with a Neutral and lowers the price target from $28 to $24.

UBS Maintains Neutral on Pfizer, Lowers Price Target to $24

Seaport Global analyst Tom Curran maintains Plug Power (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLUG#NASDAQ">PLUG</a>) with a Sell and lowers the price target from $1 to $0.75.

PLUG

Seaport Global Maintains Sell on Plug Power, Lowers Price Target to $0.75

Citigroup analyst Paul Diamond maintains Magnolia Oil &amp; Gas (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MGY#NYSE">MGY</a>) with a Sell and lowers the price target from $22 to $19.

Citigroup Maintains Sell on Magnolia Oil & Gas, Lowers Price Target to $19

Citigroup analyst Ronald Josey maintains Carvana (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVNA#NYSE">CVNA</a>) with a Buy and lowers the price target from $320 to $280.

CVNA

Citigroup Maintains Buy on Carvana, Lowers Price Target to $280

Citigroup analyst Christopher Allen maintains Nasdaq (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NDAQ#NASDAQ">NDAQ</a>) with a Neutral and lowers the price target from $84 to $75.

NDAQ

Citigroup Maintains Neutral on Nasdaq, Lowers Price Target to $75

General

BLNK

Blink Charging Receives Letter From Nasdaq Regarding Late Filing Of Form 10-K

Citigroup analyst Scott Gruber maintains Helmerich &amp; Payne (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HP#NYSE">HP</a>) with a Buy and lowers the price target from $33 to $32.

Citigroup Maintains Buy on Helmerich & Payne, Lowers Price Target to $32

Unifirst Declares Regular Cash Dividends; New $100M Share Repurchase Authorization

Citigroup analyst Scott Gruber maintains Baker Hughes (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BKR#NASDAQ">BKR</a>) with a Buy and lowers the price target from $54 to $53.

Citigroup Maintains Buy on Baker Hughes, Lowers Price Target to $53

Citigroup analyst Patrick Cunningham maintains Sherwin-Williams (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHW#NYSE">SHW</a>) with a Buy and lowers the price target from $423 to $375.

Citigroup Maintains Buy on Sherwin-Williams, Lowers Price Target to $375

Citigroup analyst Patrick Cunningham maintains PPG Indus (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PPG#NYSE">PPG</a>) with a Buy and lowers the price target from $135 to $113.

Citigroup Maintains Buy on PPG Indus, Lowers Price Target to $113

Citigroup analyst Patrick Cunningham maintains Intl Flavors &amp; Fragrances (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IFF#NYSE">IFF</a>) with a Buy and lowers the price target from $99 to $84.

Citigroup Maintains Buy on Intl Flavors & Fragrances, Lowers Price Target to $84

NSYS

Nortech Systems Reveals New Patent For Non-Magnetic Expanded Beam Fiber Optic Cable Technology.

Citigroup analyst Patrick Cunningham maintains Ecolab (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ECL#NYSE">ECL</a>) with a Buy and lowers the price target from $305 to $275.

Citigroup Maintains Buy on Ecolab, Lowers Price Target to $275

Peabody Energy Announces It Is Reviewing All Options Regarding The Acquisition Of Steelmaking Coal Assets From Anglo American

Citigroup analyst Patrick Cunningham maintains DuPont de Nemours (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DD#NYSE">DD</a>) with a Buy and lowers the price target from $95 to $74.

Citigroup Maintains Buy on DuPont de Nemours, Lowers Price Target to $74

Citigroup analyst Patrick Cunningham maintains Axalta Coating Systems (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AXTA#NYSE">AXTA</a>) with a Neutral and lowers the price target from $42 to $32.

AXTA

Citigroup Maintains Neutral on Axalta Coating Systems, Lowers Price Target to $32

As Jazz Pharmaceuticals plc (the "Company") has previously disclosed, a number of complaints, including, from June 2020 to September 2020, several complaints styled as class actions and, from March 2021 to May 2022, several additional complaints, were filed on behalf of purported direct and indirect Xyrem purchasers, alleging that the Company's actions leading up to, and entering into, patent litigation settlement agreements with generic drug manufacturers who had filed abbreviated new drug applications ("ANDAs" and such filers, "ANDA filers"), violate U.S. state and federal antitrust, consumer protection and unfair competition laws. This group of cases was consolidated for multidistrict litigation ("MDL") proceedings before the U.S. District Court for the Northern District of California (the "Court") in December 2020.
On April 7, 2025, Jazz Pharmaceuticals Ireland Limited, a wholly-owned subsidiary of the Company, entered into a preliminary class settlement agreement (the "preliminary class settlement agreement") with the class of indirect Xyrem purchasers to settle all claims of participating class members against the Company with respect to the Company's actions leading up to, and entering into, patent litigation settlement agreements with the ANDA filers.
Pursuant to the preliminary class settlement agreement, which was entered into with counsel representing the class representatives, the Company has agreed to pay a total of $145&nbsp;million in a lump sum. The Company plans to use cash on hand to fund the preliminary class settlement agreement's obligations. The Company expects to record a pre-tax charge of approximately $145&nbsp;million associated with this preliminary class settlement agreement in the first quarter of 2025.

Legal

JAZZ

Jazz Pharmaceuticals Enters Preliminary $145M Class Settlement Agreement To Resolve Antitrust And Consumer Protection Claims Related To Patent Litigation Settlements For Xyrem, Expected To Record Pre-Tax Charge In Q1 2025

Comments

Sunworks

Notizie

Ultime notizie per Sunworks (OTC:SUNWQ) Azioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO